Therapy and effect of GnHRa on sex hormone and bone mineral density in patients with endometriosis

Objective To investigate the change of sex hormone and bone mineral density(BMD) in patients with endometriosis(EM) using the gonadotropin-releasing hormone agonist(GnHRa).Methods 60 patients with EM were divided into group A(n=30) and group B(n=30),and 30 healthy female patients were selected as group C.Group A received leuprorelin acetate,group B received leuprorelin acetate combined with 7-tibolone,while group C received nothing.The clinical efficiency,levels of FSH,LH,E2 and P and BMD were observed.Results There was no significant difference in clinical efficiency between group A and group B.The levels of FSH,LH,E2 and P after 4 weeks and 12 weeks in groups A and B more significantly decreased than those before treatment and in group C.The levels of E2 and P in group B were higher than those in group A after 4 weeks and 12 weeks.The levels of BMD in groups A and B did not significantly decrease.Conclusion GnHRa can decrease the levels of FSH,LH,E2 and P,and GnHRa combined with the add-back therapy can release the decreasing extent of sex hormone and reduce the bone loss.